Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Cristina Quero-Blanco
A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Related publications
High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Targeting Tumor-Related Immunosuppression Using Metronomic Cyclophosphamide in Combination With Lenalidomide -New Mechanisms for Old Drugs
Chemotherapy: Open Access
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
An Uncommon Response to Metronomic Therapy in a Heavily Pretreated Patient With Metastatic Carcinosarcoma: A Case Report
Journal of Medical Case Reports
Medicine
Phase I/Ii Study of 2-Chloro-2′-Deoxyadenosine With Cyclophosphamide in Patients With Pretreated B Cell Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin’s Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
A Dose-Escalating Phase I of Imatinib Mesylate With Fixed Dose of Metronomic Cyclophosphamide in Targeted Olid Tumours
British Journal of Cancer
Cancer Research
Oncology
